Publication | Open Access
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
474
Citations
32
References
2022
Year
In patients with advanced melanoma, progression-free survival was significantly longer among those who received TIL therapy than among those who received ipilimumab. (Funded by the Dutch Cancer Society and others; ClinicalTrials.gov number, NCT02278887.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1